Eli Lilly's Once-Weekly Insulin Trials Show Similar A1C Reduction As Daily Doses, Improving Diabetes Management Potential
Portfolio Pulse from Benzinga Newsdesk
Eli Lilly's phase 3 trials for once-weekly insulin efsitora show similar A1C reduction as daily doses, potentially improving diabetes management. The trials demonstrated non-inferior A1C reduction compared to daily basal insulins, with a favorable safety profile.
September 05, 2024 | 10:50 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Eli Lilly's once-weekly insulin efsitora demonstrated non-inferior A1C reduction compared to daily basal insulins in phase 3 trials, with a favorable safety profile. This could enhance diabetes management and potentially boost Eli Lilly's market position.
The positive results from the phase 3 trials of Eli Lilly's once-weekly insulin efsitora indicate a potential improvement in diabetes management, which could lead to increased adoption and sales. This is likely to have a positive impact on Eli Lilly's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100